★ Breakthrough Medical Research • 15 Landmark Multi-Trial Guides • 6,255 Indexed Studies

FDA MedWatch Safety Alerts & Drug Recalls (60 Indexed Studies)

Q: Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

Q: How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Q: Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

Q: How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.

Official FDA Class I, Class II, and Class III drug recalls, lot-specific impurity notices, and MedWatch safety communications. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.

★ #1 Lead Breakthrough Study • NEJM SURMOUNT-1 (176 Weeks) N = 1,032 Adults • p < 0.001

Once-Weekly Tirzepatide Cuts Type 2 Diabetes Progression by 94% Over 3 Years—With a 22.9% Sustained Weight Reduction

The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).

Read the Full Breakthrough Breakdown → Jump to All 15 Landmark Breakthroughs ↓

Inside the Clinical Evidence Lab: Our research desk audits 6,255 human trials from NEJM, The Lancet, JAMA, and NCBI PubMed—reporting true Absolute Risk Reduction (ARR) and sample sizes (N) without pharma spin.

1. Major Clinical Breakthroughs & Deep-Dive Study Breakdowns (16 Guides)

Landmark Clinical Breakthroughs & Head-to-Head Trial Reviews

Plain-English breakdowns of the most important human trials—showing actual benefit percentages (ARR/NNT), dosing rules, and who should be careful.

Double-Blind Placebo-Controlled Sleep & Glycine RCTs N = 620 Adults Across 3 Human Trials

Why Magnesium Glycinate Calms Racing 2:00 A.M. Thoughts Without Leaving You Groggy the Next Morning

Bottom-Line Trial Result: Sleep Onset Latency: -17.4 Minutes (p = 0.002) • Serum Cortisol: -18% vs. Placebo • Serum Melatonin: +34% (p < 0.01)

A clinical evidence breakdown of how elemental magnesium blocks excitatory NMDA glutamate receptors while its glycine amino acid carrier lowers core body temperature via the suprachiasmatic nucleus—plus real RCT numbers on sleep latency, cortisol, and supplement label math.

Supplement: Magnesium Glycinate Condition: Insomnia

8 Min Read • 1,380 Words Read Study Guide →

Isotope Fractional Absorption & Metabolic Balance RCTs N = 480 Subjects Across 4 Human PK Trials

Magnesium Glycinate vs. Citrate vs. Oxide: What Human Bioavailability Trials Show About Absorption and Stomach Upset

Bottom-Line Trial Result: Fractional Absorption: Magnesium Oxide ~4% vs. Chelated Bisglycinate ~23.5% (+488% Relative Bioavailability, p < 0.001)

Why inorganic Magnesium Oxide absorbs at just 4% in human fractional absorption studies—and how amino-acid chelation allows Magnesium Bisglycinate to cross the intestinal wall via PEPT1 dipeptide channels without drawing water into the colon.

Supplement: Magnesium Glycinate Condition: GERD & Gut Motility

8 Min Read • 1,260 Words Read Study Guide →

Randomized Double-Blind Precision Nutrition Trial N = 1,180 Participants Across 4 Studies

Why Vitamin D3 Barely Works When You Are Low in Magnesium—Plus What Clinical Trials Show for Nighttime Leg Cramps

Bottom-Line Trial Result: CYP2R1 / CYP27B1 Activation: Sufficient Mg lowers risk of Vitamin D insufficiency (<30 ng/mL) by 46% (p < 0.001)

Every hepatic and renal enzyme that converts cholecalciferol (Vitamin D3) into active 1,25-dihydroxyvitamin D requires magnesium as an obligatory cofactor—explaining "Vitamin D resistance" and nocturnal calf muscle hyperexcitability.

Supplement: Vitamin D3 Supplement: Magnesium Glycinate

8 Min Read • 1,290 Words Read Study Guide →

Pharmacokinetic & GI Tolerability Crossover Trials N = 1,680 Patients Across 4 Trials

Why Metformin (Glucophage & Glycomet) Upsets Your Stomach—and the Extended-Release (ER) Switch That Cuts GI Side Effects in Half

Bottom-Line Trial Result: GI Adverse Events: 26.3% -> 11.7% After IR-to-ER Switch (ARR: 14.6%, RRR: 55%, p < 0.001) • Diarrhea 18.4% -> 6.9%

A clinical synthesis of human pharmacokinetic crossover trials (Timmins et al., PMID: 16176111), GI tolerability cohorts (Blonde et al., PMID: 15140331), and dose-response studies (Garber et al., PMID: 9428832) explaining why unabsorbed gut Metformin triggers diarrhea and how GelShield ER matrices resolve it.

Rx: Metformin ER Condition: Type 2 Diabetes

7 Min Read • ~1,150 Words Read Study Guide →

DPPOS 13-Year Longitudinal Cohort & HOME RCT N = 2,155 Patients (4.3–13 Years)

Metformin (Glucophage & Glycomet) and Vitamin B12 Deficiency: Why Fatigue and Tingling Feet Get Missed

Bottom-Line Trial Result: Total Serum B12: -19% vs. Placebo (p < 0.001) • Biochemical Deficiency (<203 pg/mL): 13% increased risk per year of exposure

A clinical synthesis of the 13-year Diabetes Prevention Program Outcomes Study (Aroda et al., PMID: 26900641), the 4.3-year BMJ randomized controlled trial (de Jager et al., PMID: 20488910), and ileal calcium-channel absorption studies (Bauman et al., PMID: 10977046) explaining how Metformin depletes Vitamin B12 and how to fix it.

Rx: Metformin ER Supplement: Vitamin B12

7 Min Read • ~1,150 Words Read Study Guide →

UKPDS 34 (10.7-Yr RCT) & Bannister Cohort N = 180,000+ Cohort + 1,704 RCT Patients

Metformin (Glucophage & Glycomet) Longevity & Heart Research: What UKPDS, TAME, and Exercise Trials Actually Show

Bottom-Line Trial Result: All-Cause Mortality: RRR 36% (p = 0.011) • Myocardial Infarction: RRR 39% (p = 0.010) • DPP-4 VO2max Attenuation Caveat

A clinical synthesis of the 10.7-year UKPDS 34 cardiovascular mortality trial (PMID: 9742977), the TAME geroprotective protocol (Barzilai et al., PMID: 27304507), and the older-adult exercise blunting trial (Konopka et al., PMID: 30548390)—separating proven diabetic survival gains from healthy-person anti-aging hype.

Rx: Metformin ER Condition: Type 2 Diabetes

8 Min Read • ~1,200 Words Read Study Guide →

24-Hour Continuous Glucose Monitoring (CGM) Study N = 248 Non-Insulin T2D Patients

Why Is My Blood Sugar High in the Morning—Even When I Didn’t Eat Breakfast? (The Dawn Phenomenon Explained)

Bottom-Line Trial Result: Morning Glucose Surge: +20 to +45 mg/dL Between 3:00 AM and 8:00 AM • Adds +0.4% to Overall HbA1c (p < 0.001)

Waking up to a 145 or 165 mg/dL fasting reading after an early, healthy dinner feels deeply frustrating. Continuous glucose monitoring (CGM) studies show that in 55% of Type 2 diabetes patients, a 3:00 A.M. to 8:00 A.M. surge of growth hormone and cortisol triggers the liver to dump stored sugar (+20 mg/dL fasting glucose and +0.4% HbA1c). Here is how to tell the Dawn Phenomenon apart from the Somogyi rebound—and 4 evening adjustments that calm it down.

Condition: Type 2 Diabetes Rx: Metformin ER

7 Min Read • ~1,250 Words Read Study Guide →

Randomized Crossover CGM Exercise Timing Trials N = 840 Participants Across 3 Crossover Trials

The 15-Minute After-Dinner Walk That Cuts Blood Sugar Spikes by 22% to 30%—Without Needing Extra Insulin

Bottom-Line Trial Result: Post-Dinner Glucose iAUC: -22% to -30% With a 10–15 Min Walk vs. Sitting (p < 0.001) • Beats a Single 45-Min Morning Walk

Why sitting on the couch right after dinner traps glucose in your bloodstream—and how a relaxed 10-to-15-minute neighborhood stroll opens a mechanical "side door" (contraction-mediated GLUT4 translocation) in your leg muscles right as meal carbohydrates peak.

Condition: Type 2 Diabetes Condition: Prediabetes

7 Min Read • ~1,250 Words Read Study Guide →

DiRECT Cluster-Randomized Trial & ADA Standards of Care N = 298 DiRECT RCT + ADA Guideline Cohort

Just Told You Have Type 2 Diabetes? Take a Breath—Here Is Your Calm, Evidence-Audited First-30-Days Clinical Plan

Bottom-Line Trial Result: Drug-Free T2D Remission (<6.5% HbA1c): 46% Overall (vs. 4% control, ARR: 42%, p < 0.0001) • 86% Remission With >=15 kg Loss

Seeing an HbA1c of 6.5% or higher on your lab portal can feel like a punch to the stomach. You do not have to throw out your pantry tonight or starve yourself tomorrow. Here is a calm, week-by-week First-30-Days plan grounded in American Diabetes Association (ADA) Standards of Care, the Lancet DiRECT remission trial, and stomach-safe Extended-Release Metformin rules.

Condition: Type 2 Diabetes Rx: Metformin ER

8 Min Read • ~1,300 Words Read Study Guide →

NEJM 3-Year Phase 3 RCT (SURMOUNT-1) N = 1,032 Adults (176 Weeks)

NEJM 3-Year SURMOUNT-1 Study: Once-Weekly Tirzepatide Cuts Progression From Prediabetes to Type 2 Diabetes by 94%

Bottom-Line Trial Result: ARR: 11.4% (1.2% vs. 12.6% placebo) • RRR: 94% (HR 0.06, p < 0.001) • NNT = 9 • -22.9% Body Weight

In a landmark 176-week randomized double-blind trial published in the New England Journal of Medicine (N = 1,032 adults with prediabetes and obesity), once-weekly tirzepatide (Mounjaro / Zepbound) reduced progression to Type 2 diabetes by 94% (1.2% vs. 12.6% placebo, HR 0.06, p < 0.001) while sustaining up to 19.7% weight loss. Here are the exact numbers, the 17-week off-treatment rebound data, and what it means for real patients.

Rx: Tirzepatide Condition: Type 2 Diabetes

8 Min Read • ~1,300 Words Read Study Guide →

Clinician Time-Motion & Shared Decision-Making Trials N = 4,820 Clinical Encounters

7 Questions to Bring to Your Next Doctor Visit (So You Never Leave a 15-Minute Appointment Confused)

Bottom-Line Trial Result: Median Time Before Clinician Interruption: 11 Seconds (36% Solicited Agenda) • Written Agenda Cuts Diagnostic Error by 38%

Primary-care time-motion trials show clinicians interrupt a patient’s opening statement after a median of just 11 seconds (PMID: 29972200), and patients immediately forget 40% to 80% of spoken medical instructions (PMID: 12724490). Here are the 7 evidence-backed questions that transform a rushed 15-minute visit into a clear, safe diagnostic and treatment plan.

Doctors Hub (CPT Volume & Bedside) Conditions Hub (Lab Cutoffs)

7 Min Read • ~1,220 Words Read Study Guide →

FDA Food-Effect Bioavailability Crossover Studies N = 3,150 Crossover PK Subjects

What Does "Take With Food" Really Mean on Your Prescription Bottle? (FDA Pharmacokinetics Explained)

Bottom-Line Trial Result: Bile-Salt Drug Absorption (Rivaroxaban 20 mg): 66% Fasting -> ~100% With 500-kcal Meal • Levothyroxine Fasting Gap: +25% TSH Stability

Does "take with food" mean two crackers, a glass of milk, or a full dinner? Under FDA Food-Effect Bioavailability standards and human pharmacokinetic trials, meal timing can shift a drug’s bloodstream absorption (AUC) by -50% to +300% or slash stomach side effects in half (PMID: 12548010, PMID: 9428832). Here is the exact pill-by-pill decoder.

Rx: Metformin ER Rx: Levothyroxine

7 Min Read • ~1,240 Words Read Study Guide →

FDA 12-Year Analysis of 2,070 Human Bioequivalence Trials N = 2,070 Human Crossover Trials

Generic vs. Brand-Name Medications: The 3.5% Bioequivalence Rule & When Pill Fillers Actually Matter

Bottom-Line Trial Result: Mean Generic vs. Brand Difference: 3.56% AUC & 4.35% Cmax (98% Within <10%) • Narrow Therapeutic Index (NTI) Exceptions Decoded

A pervasive myth claims FDA generic drugs are allowed to vary by "up to 20%" from the brand name. In reality, an FDA study of 2,070 human bioequivalence trials (Davit et al., Annals of Pharmacotherapy, PMID: 19776300) proved the average absorption difference between brand and generic is just 3.5%—equivalent to two batches of the brand pill itself. Here is when generics are identical, and the 3 rare exceptions to ask your pharmacist about.

Medications Hub (NADAC Wholesale Prices) Rx: Bupropion XL

7 Min Read • ~1,260 Words Read Study Guide →

Optical PPG vs. 12-Lead Holter ECG Validation Trials N = 1,420 Wearable vs. ECG Recordings

Why Your Smartwatch "Readiness Score" & Heart Rate Variability (HRV) Can Mislead You: Optical PPG vs. Clinical ECG Data

Bottom-Line Trial Result: Nocturnal Resting rMSSD Correlation: r = 0.94–0.98 vs. Gold-Standard ECG • Daytime Motion Artifact Error: 22%–38% Packet Loss

Millions of adults wake up and let a wrist or finger wearable tell them how "recovered" they are based on overnight Heart Rate Variability (rMSSD). Yet clinical validation studies comparing green/infrared optical photoplethysmography (PPG) against gold-standard 12-lead Holter ECG (PMID: 40321810, PMID: 37687769, PMID: 28838896) expose critical blind spots: motion artifacts, premature beats, alcohol, and unvalidated proprietary "Readiness" algorithms.

Condition: Heart & Vascular Hub Supplement: Magnesium Glycinate

8 Min Read • ~1,280 Words Read Study Guide →

NEJM & Lancet Oral GLP-1 Trials N = 831 Adults (36–40 Weeks)

Once-Daily Oral GLP-1 Pill (Orforglipron) Cuts Body Weight by Up to 14.7% Without Fasting Rules: Inside the NEJM & Lancet Trials

Bottom-Line Trial Result: Weight Change: -14.7% vs. -2.3% placebo (Net -12.4%, p < 0.001) • HbA1c -1.8% • Zero Food/Water Fasting Restriction

Unlike weekly GLP-1 injections (Ozempic, Wegovy, Zepbound) or peptide pills that require strict morning fasting (Rybelsus), orforglipron is a small-molecule non-peptide GLP-1 receptor agonist that can be swallowed at any time of day with or without food. Across NEJM and Lancet randomized trials (PMID: 37351564, PMID: 37351565, PMID: 41275875), once-daily orforglipron reduced body weight by up to 14.7% at 36 weeks and lowered HbA1c by -2.10 percentage points.

Rx: Semaglutide Rx: Tirzepatide

8 Min Read • ~1,290 Words Read Study Guide →

NEJM Phase 3 Outcomes Audit • N = 17,604 Randomized Adults

NEJM SELECT Trial (N = 17,604): Once-Weekly Semaglutide Cuts Heart Attacks, Strokes & Cardiovascular Death by 20% in Adults Without Diabetes

Why the FDA granted Wegovy (semaglutide 2.4 mg) its historic cardiovascular risk-reduction label—and what the 20% Relative Risk Reduction vs. 1.5% Absolute Risk Reduction (NNT = 67 over 3.3 years) actually means at your kitchen table.

Atrial Fibrillation & Cardiometabolic Flagship Hub NEJM SURMOUNT-1 Prediabetes Trial (Tirzepatide -94% RRR)

8 Min Read • 1,340 Words Read Study Guide →

3. All Indexed Clinical Studies (60)

FDA MedWatch Safety Alerts & Drug Recalls (60)

Page 1 of 2 • Sorted by Participant Sample Size (N)

FDA Safety Alert & Drug Recall FDA_MEDWATCH-2176137436

FDA MedWatch Safety Alerts (Safety Alert): Early Alert: Compact Medical Removes and Updates Use Instructions for ButterflyBVM Bag-Valve-Mask Resuscitators

Compact Medical removes and updates use instructions for certain ButterflyBVM devices due to development of holes in bellows.

FDA MedWatch Safety Alerts • 2026-11-03 Read Study

FDA Safety Alert & Drug Recall FDA_MEDWATCH-2803434992

FDA MedWatch Safety Alerts (Safety Alert): Early Alert: B. Braun Medical Inc. Removes Streamline Bloodline Set for Dialog+

The dialyzer connector may not be attached appropriately, resulting in leaking and potential blood loss.

FDA MedWatch Safety Alerts • 2026-11-02 Read Study

FDA Safety Alert & Drug Recall FDA_MEDWATCH-2705894539

FDA MedWatch Safety Alerts (Safety Alert): FDA Advises Consumers Not to Buy or Serve Once Upon a Farm Tractor Wheels Organic Toddler Soft-Baked Bars

Consumers Should Not Buy or Serve Once Upon a Farm Tractor Wheels, Organic Toddler Soft-Baked Bars Due to a Potentially Fatal Choking Hazard

FDA MedWatch Safety Alerts • 2026-11-02 Read Study

FDA Safety Alert & Drug Recall FDA_RECALLS-356689524

FDA Drug Recalls (Recall): Snack Right Super Foods, Inc. dba Brad's Raw Chips Recalls Brad's Crunchy Kale & Veggie Chips Due to Potential Thallium Contamination

Coral Gables, FL - Snack Right Super Foods, Inc., doing business as Brad's Raw Chips, is recalling certain Brad's Plant Based Crunchy Kale (2 oz) and Brad's Veggie Chips Kale (3 oz) products because they may contain thallium.

FDA Drug Recalls • 2026-11-02 Read Study

FDA Safety Alert & Drug Recall FDA_RECALLS-942024156

Can Ashwagandha Really Calm Daily Stress Without Leaving You Groggy?

Vitality Works Inc. of Albuquerque, New Mexico, is recalling one lot (lot number 2025-26227) of 365 Whole Foods Market Standardized + Full Spectrum Blend Ashwagandha Capsules 120 count because it has the potential to be contaminated with Salmonella, an organis

FDA Drug Recalls • 2026-10-30 Read Study

FDA Safety Alert & Drug Recall FDA_RECALLS-1536156331

FDA Drug Recalls (Recall): Once Upon A Farm Recalls All Lots and Varieties of Tractor Wheels Organic Toddler Soft-Baked Bars Due to Potential Choking Hazard

Once Upon a Farm (Berkeley, CA) is recalling all lots and varieties of fruit-flavored Tractor Wheel Organic Toddler Soft-Baked bars due to reports that the composition of the Tractor Wheel toddler snack can rapidly hydrate into a dense, dry, and sticky mass up

FDA Drug Recalls • 2026-10-30 Read Study

FDA Safety Alert & Drug Recall FDA_MEDWATCH-1688403489

Check Your Medicine Cabinet: Hospital Glucose Meter Correction: Nova Biomedical Updates Use Instructions for StatStri

Update use instructions for StatStrip Glucose Hospital Meter Systems due to the potential for glucose results to be assigned to the incorrect patient.

FDA MedWatch Safety Alerts • 2026-10-30 Read Study

FDA Safety Alert & Drug Recall FDA_MEDWATCH-1365219842

Check Your Medicine Cabinet: Platelet Factor 4 (PF4) Radioimmunoassay Recall: Instrumentation Laboratories Removes He

Product performance issue may lead to a false negative result which will delay recognition of heparin-induced thrombocytopenia.

FDA MedWatch Safety Alerts • 2026-10-30 Read Study

FDA Safety Alert & Drug Recall FDA_MEDWATCH-2606293946

Check Your Medicine Cabinet: Early Alert: Medline Removes or Corrects All Medline Brand Beds and Accessories

Medline removes or corrects all brand beds & accessories due to fire, electrical overheating, entrapment & asphyxiation risks. Risk of serious injury or death.

FDA MedWatch Safety Alerts • 2026-10-29 Read Study

FDA Safety Alert & Drug Recall FDA_RECALLS-2886596190

Check Your Medicine Cabinet: SLR Food Distribution Inc. Recalls Wise Wife Brand Ground Cinnamon Due to Elevated Lead

SLR Food Distribution Inc. of Hicksville, New York, is voluntarily recalling Wise Wife Brand Ground Cinnamon because it has the potential to be contaminated with elevated levels of lead.

FDA Drug Recalls • 2026-10-29 Read Study

FDA Safety Alert & Drug Recall FDARECALL-D-0068-2027